查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1975274

全球僵直性脊椎炎市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Ankylosing Spondylitis Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 113 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计僵直性脊椎炎市场将从 2025 年的 71.1 亿美元成长到 2034 年的 127.1 亿美元，2026 年至 2034 年的复合年增长率为 6.66%。

僵直性脊椎炎)的全球市场持续稳定成长，这主要得益于诊断率的提高和人们对发炎性自体免疫疾病认识的增强。影像技术的进步和早期筛检通讯协定的建立使得僵直性脊椎炎的早期发现成为可能，尤其是在年轻患者群体中。慢性腰痛盛行率的不断上升，以及遗传易感性的存在，进一步推动了已开发市场和新兴市场对生物目标製剂和先进治疗方法的需求。

成长要素包括TNF抑制剂和IL-17抑制剂等生物製药疗法的广泛应用，以及已开发国家医保覆盖范围的扩大。製药公司正大力投资研发，以推出疗效和安全性更高的新一代生物製药。此外，患者支持活动和宣传宣传活动提高了公众对疾病的认识，加快了治疗启动速度，并扩大了目标患者群体。

展望未来，生物相似药的上市、精准医疗方法的应用以及免疫学研究的进展预计将推动市场强劲成长。新兴市场有望受益于医疗基础设施的改善和医疗费用支出的增加而显着增长。与数位医疗的融合，实现远端监测和用药依从性追踪，将进一步改善患者疗效，并推动僵直性脊椎炎市场实现持续的长期成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球僵直性脊椎炎市场：依药物类别划分

  • 市场分析、洞察与预测
  • 非类固醇消炎剂（NSAIDs）
  • TNF抑制剂
  • 其他药物类别

第五章 全球僵直性脊椎炎市场：依通路划分

  • 市场分析、洞察与预测
  • 医院药房
  • 零售药房
  • 其他的

第六章 全球僵直性脊椎炎市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 亚太其他地区
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • AbbVie Inc
    • Amgen Inc
    • Pfizer Inc
    • UCB Inc
    • Novartis AG
    • Eli Lilly And Company
    • Johnson And Johnson Services Inc
    • Merck And Co. Inc
    • Izana Biosciences
    • Zydus Lifescience Ltd
简介目录
Product Code: VMR112112244

The Ankylosing Spondylitis Market size is expected to reach USD 12.71 Billion in 2034 from USD 7.11 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The Global Ankylosing Spondylitis Market is experiencing steady expansion driven by rising diagnosis rates and increasing awareness of inflammatory autoimmune disorders. Improved imaging technologies and earlier screening protocols are enabling timely identification of ankylosing spondylitis, particularly among younger populations. The growing burden of chronic back pain and genetic predisposition factors are further contributing to demand for targeted biologics and advanced therapeutic interventions across developed and emerging healthcare systems.

Key growth drivers include the strong adoption of biologic therapies such as TNF inhibitors and IL-17 inhibitors, alongside expanding reimbursement coverage in developed economies. Pharmaceutical companies are investing heavily in research and development to introduce next-generation biologics with improved efficacy and safety profiles. Additionally, patient advocacy initiatives and educational campaigns are improving disease awareness, thereby accelerating treatment uptake and expanding the addressable patient pool.

Looking ahead, the market is poised for robust growth fueled by biosimilar launches, precision medicine approaches, and advancements in immunology research. Emerging markets are expected to contribute significantly due to improving healthcare infrastructure and rising healthcare expenditure. Digital health integration for remote monitoring and adherence tracking will further enhance patient outcomes, positioning the ankylosing spondylitis market for sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • Non-Steroidal Anti-Inflammatory Drug (NSAID)
  • TNF Inhibitors
  • Other Drug Classes

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

COMPANIES PROFILED

  • AbbVie Inc, Amgen Inc, Pfizer Inc, UCB Inc, Novartis AG, Eli Lilly and Company, Johnson and Johnson Services Inc, Merck and Co Inc, Izana Biosciences, Zydus Lifescience Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Non-Steroidal Anti-Inflammatory Drug (NSAID) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. TNF Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Distribution Channel
  • 5.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Drug Class
    • 6.2.2 By Distribution Channel
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Drug Class
    • 6.3.2 By Distribution Channel
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Drug Class
    • 6.4.2 By Distribution Channel
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Drug Class
    • 6.5.2 By Distribution Channel
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Drug Class
    • 6.6.2 By Distribution Channel
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ANKYLOSING SPONDYLITIS INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 AbbVie Inc
    • 8.2.2 Amgen Inc
    • 8.2.3 Pfizer Inc
    • 8.2.4 UCB Inc
    • 8.2.5 Novartis AG
    • 8.2.6 Eli Lilly And Company
    • 8.2.7 Johnson And Johnson Services Inc
    • 8.2.8 Merck And Co. Inc
    • 8.2.9 Izana Biosciences
    • 8.2.10 Zydus Lifescience Ltd